TrialClinical and experimental nephrology2019

Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.

Takashi Shigematsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.